Advertisement


Anthony D. Elias, MD, on Triple-Negative Breast Cancer: Treatment Update

NCCN 2018 Annual Conference

Advertisement

Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews promising experimental treatments, as well as PARP inhibitor therapy in TNBC, including the implications of newly approved olaparib for gBRCA-mutant breast cancer.



Related Videos

Skin Cancer

April K.S. Salama, MD, on Melanoma: Treating Recurrent or Progressive Distant Disease

April K.S. Salama, MD, of Duke Cancer Institute, talks about how to select systemic therapy for a patient with previously treated metastatic melanoma.

Prostate Cancer

James L. Mohler, MD, on Prostate Cancer: Management Approaches

James L. Mohler, MD, of Roswell Park Cancer Institute, discusses personalized medicine, molecular risk stratification, and better androgen-deprivation therapy for men with prostate...

Breast Cancer

William J. Gradishar, MD, on Hormone-Sensitive Breast Cancer: Treatment Update

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses recent evidence on the efficacy, safety, and utility of HER2-targ...

Hepatobiliary Cancer

Anne M. Covey, MD, on HCC: Screening and Diagnosis Updates

Anne M. Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest recommendations for screening and diagnosing hepatocellular carcinoma, an aggressive tumor marked...

Colorectal Cancer
Immunotherapy

Alan P. Venook, MD, on Selecting Treatment for Advanced Colorectal Cancer

Alan P. Venook, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses which biomarkers to order and when, the role of checkpoint inhibitors, and chemotherapy c...

Advertisement

Advertisement



;
Advertisement